Skip to main content

Table 1 Patient information

From: FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Patient #

Study arm

Soft tissue mets. at baseline

Bone mets. at baseline

IRAE greater than Gr 1a (week of occurrence)

Progression-free survival (weeks)

1

1

Yes

Yes

None

24

2

1

Yes

Yes

None

48

3

1

No

Yes

None

24

4

1

Yes

No

None

48+

5

1

Yes

Yes

None

16

6

1

No

Yes

Hyperthyroidism (6); Hypothyroidism (12)

24

7

2

No

Yes

Hypothyroidism (36)

36+

8

2

Yes

Yes

Pancreatitis (30)

48

9

2

Yes

Yes

None

24

10

2

Yes

Yes

None

24+

11

2

No

Yes

Hyperthyroidism (18)

48

12

2

No

Yes

Adrenal Insufficiency (38)

72+

13

3

Yes

Yes

Elevated TSH (9)

36+

14

3

Yes

No

None

24

15

3

Yes

Yes

None

24

16

3

Yes

No

Hyperthyroidism (3)

12

17

3

No

Yes

None

12

  1. aImmune-related adverse events that were at least possibly related to pembrolizumab and /or pTVG vaccine are listed